Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Magnolol suppresses TKI-resistant EGFR-mutant lung cancer by inhibiting EGFR and AXL-cMyc.

European journal of pharmacology - 28 Feb 2026

Chen Chin-Chuan, Wang Tong-Hong, Leu Yann-Lii, Chan Chieh-Wen, Chen Yu-Xuan, Chu Yu-De, Chen Chi-Yuan

Abstract excerpt

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), particularly osimertinib, remains a major therapeutic challenge in EGFR-mutant lung cancer. In this study, we evaluated the pharmacological activity of magnolol, a natural biphenolic compound, in EGFR-mutant lung cancer models, including osimertinib-resistant cells harboring tertiary mutations such as C797S. Magnolol...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Axl Receptor Tyrosine Kinase
Share to Biphenyl Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Mice, Nude

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins

Share to Receptor Protein-Tyrosine Kinases

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 41611070
DOI: 10.1016/j.ejphar.2026.178607

Genes

EGFR
AXL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Magnolol suppresses TKI-resistant EGFR-mutant lung cancer by inhibiting EGFR and AXL-cMyc.PMID 41611070Read ↗

HS-10296 (almonertinib) enhances radiosensitivity in EGFR-mutant nonsmall cell lung cancer (including T790M) through inhibition of EGFR downstream signaling and DNA damage repair.Semantic proximity Read ↗

Cudratricusxanthone A Exhibits Antitumor Activities Against NSCLC Harboring EGFR L792H and G796R Triple Mutations via Regulating EGFR-ERK/AKT/STAT3 Signaling.Semantic proximity Read ↗

AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.Semantic proximity Read ↗

HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations.Semantic proximity Read ↗

MCB-613 exploits a collateral sensitivity in drug resistant <i>EGFR</i> -mutant non-small cell lung cancer through covalent inhibition of KEAP1Semantic proximity Read ↗

Potentiation of EGFR mutant lung cancer treatment targeting replication stressSemantic proximity Read ↗

EGFR Mutations Compromise Hypoxia-Associated Radiation Resistance through Impaired Replication Fork-Associated DNA Damage Repair.Semantic proximity Read ↗

ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC.Semantic proximity Read ↗

Dual actionability of BMI1 activation and mitotic vulnerability defines adaptive Osimertinib resistance in EGFR-mutant NSCLC.Semantic proximity Read ↗

EGFR suppression contributes to growth inhibitory activity of G-quadruplex ligands in non-small cell lung cancers.Semantic proximity Read ↗

Machine learning-aided discovery of T790M-mutant EGFR inhibitor CDDO-Me effectively suppresses non-small cell lung cancer growth.Semantic proximity Read ↗

Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.